Nuvectis Pharma Future Growth
Future criteria checks 0/6
Nuvectis Pharma is forecast to grow earnings and revenue by 38.1% and 74.5% per annum respectively while EPS is expected to grow by 39% per annum.
Key information
38.1%
Earnings growth rate
39.0%
EPS growth rate
| Biotechs earnings growth | 27.9% |
| Revenue growth rate | 74.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 12 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans
Oct 20
We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully
Jun 26Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
Jan 06Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Oct 03We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
Jan 31Nuvectis Pharma forms scientific advisory board for research and development of drugs
Sep 28Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04
Aug 05Nuvectis Pharma declines 13%, announces $15.9M private placement
Jul 27We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
May 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2 | -25 | N/A | N/A | 3 |
| 12/31/2025 | N/A | -22 | N/A | N/A | 3 |
| 12/31/2024 | N/A | -19 | N/A | N/A | 3 |
| 6/30/2024 | N/A | -21 | -14 | -14 | N/A |
| 3/31/2024 | N/A | -22 | -16 | -16 | N/A |
| 12/31/2023 | N/A | -22 | -16 | -16 | N/A |
| 9/30/2023 | N/A | -22 | -16 | -16 | N/A |
| 6/30/2023 | N/A | -22 | -17 | -17 | N/A |
| 3/31/2023 | N/A | -20 | -15 | -15 | N/A |
| 12/31/2022 | N/A | -19 | -14 | -14 | N/A |
| 9/30/2022 | N/A | -15 | -11 | -11 | N/A |
| 6/30/2022 | N/A | -13 | -11 | -11 | N/A |
| 3/31/2022 | N/A | -16 | -13 | -13 | N/A |
| 12/31/2021 | N/A | -13 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NVCT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NVCT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NVCT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NVCT is forecast to have no revenue next year.
High Growth Revenue: NVCT is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NVCT's Return on Equity is forecast to be high in 3 years time